We therefore manufactured universal BE-CAR formulations against CD33 (siglec-3) or C-type lectin-like molecule-1 (CLL-1/CLEC12A), both of which are commonly over-expressed in childhood and adult AML [3, 4]. The gene discussed is CLEC12A; the disease is acute myeloid leukemia.